Retinal Disorder Treatment Market – Trends Report, 2032 (2024)

Home > Healthcare > Pharmaceuticals > Finished Drug Form > Retinal Disorder Treatment Market

Report ID: GMI10121
Published Date: Jul 2024
Report Format: PDF

Retinal Disorder Treatment Market Size

Retinal Disorder Treatment Market size was valued at around USD 13.7 billion in 2023 and is estimated to grow at 9.6% CAGR from 2024 to 2032. Retinal disorder treatment encompasses the medical and surgical interventions used to diagnose, manage, and treat various conditions affecting the retina, the light-sensitive layer at the back of the eye essential for vision. The primary goal of these treatments is to preserve or restore vision, prevent further vision loss, and improve the quality of life for patients suffering from retinal disorders.

To get key market trends

Download Free Sample

The rising incidence of diabetes is a significant driver for the market. For instance, according to World Health Organization (WHO), in 2021 reported that 537 million adults aged 20-79 are affected by diabetes, equating to approximately one in ten adults. Projections indicate that this figure could increase to 643 million by 2030 and 783 million by 2045. Therefore, this underscores the critical need for advancements in the retinal disorder treatment to address the growing prevalence of diabetes-related eye complications. Furthermore, rising geriatric population base, technological advancements, and rising awareness and screening programs, are driving factors for the market growth.

Retinal Disorder Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2023
Retinal Disorder Treatment Market Size in 2023:	USD 13.7 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	9.6%
2032 Value Projection:	USD 31.1 Billion
Historical Data for:	2021 - 2023
No. of Pages:	175
Tables, Charts & Figures:	227
Segments covered:	Type, Dosage Form, Distribution Channel, and Region
Growth Drivers:	Increasing prevalence of diabetes Rising geriatric population Technological advancements Rising awareness and screening programs
Pitfalls & Challenges:	High treatment cost Side effects and safety concerns

Retinal Disorder Treatment Market Trends

The field of retinal disorder treatment has witnessed remarkable advancements driven by innovative technologies. From groundbreaking developments in gene therapy, which is estimated to reach USD 44.5 billion by 2032, and stem cell research to the integration of artificial intelligence in healthcare and robotic surgery, these technologies are revolutionizing the diagnosis and treatment affecting the retina.

Advanced novel drug delivery systems have revolutionized treatment efficacy and patient convenience. Sustained-release implants and microneedle patches allow for controlled and targeted delivery of therapeutic agents directly to the retina, optimizing drug concentration while minimizing systemic side effects.
Artificial intelligence in healthcare and machine learning algorithms have enhanced the diagnostic capabilities in ophthalmology. By analyzing retinal images, AI can detect subtle changes indicative of disease progression, enabling earlier intervention and personalized treatment plans. AI-driven diagnostic tools are improving the accuracy and efficiency of screening programs for conditions such as diabetic retinopathy, ensuring timely management to prevent vision loss.
Additionally, stem cell research holds immense potential in regenerative medicine for treating retinal diseases. Stem cells, capable of differentiating into various cell types, including retinal cells, offer a novel approach to replacing damaged or degenerated retinal tissues.

Retinal Disorder Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free Sample

Based on type, the retinal disorder treatment industry is divided into diabetic retinopathy, macular degeneration, diabetic macular edema, retinal vein occlusion, and other types. Further, macular degeneration is segmented into dry macular degeneration and wet macular degeneration. The diabetic retinopathy segment of the market is forecasted to reach USD 11 billion by 2032.

Advances in imaging technologies and telemedicine have facilitated early detection of diabetic retinopathy. Screening programs, often utilizing AI for image analysis, enable timely identification of microvascular changes in the retina before symptoms manifest.
Many of the treatment modalities for diabetic retinopathy such as intravitreal injections and laser therapy, are minimally invasive. This reduces the risk of complications associated with traditional surgical interventions, enhances patient comfort, and allows for outpatient management in many cases.
Further, the integration of AI and telemedicine supports personalized treatment plans for diabetic retinopathy patients. AI algorithms analyze retinal images to predict disease progression and guide clinicians in tailoring treatment strategies based on individual patient characteristics and response to therapy, thus driving the market growth.

Learn more about the key segments shaping this market

Download Free Sample

Based on dosage form, the retinal disorder treatment market is bifurcated into capsules & tablets, eye drops, eye solutions, gels, and ointments. The eye drops segment accounted for USD 3.8 billion in 2023.

Eye drops provide a non-invasive method of delivering medications directly to the eye, specifically targeting the affected area without the need for injections or surgical procedures. This enhances patient comfort and compliance, particularly for individuals who may be averse to invasive treatments.
Using eye drops is convenient and accessible, allowing patients to administer medications at home without frequent visits to healthcare facilities. This convenience promotes adherence to treatment regimens, ensuring consistent delivery of therapeutic agents to manage retinal disorders effectively.
Additionally, eye drops enable localized delivery of medications to the surface of the eye and potentially to deeper structures within the eye such as the retina. This targeted delivery minimizes systemic side effects compared to oral medications and allows for higher concentrations of drugs at the site of action. Thus, propelling the growth of the market.

Based on distribution channel, the retinal disorder treatment market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is forecasted to reach USD 13.2 billion by 2032.

Hospital pharmacies stock a wide range of specialized medications and formulations specifically used in the treatment of retinal disorders. This includes drugs for conditions such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion (RVO), may require precise dosing and administration protocols.
Pharmacists in hospital settings collaborate closely with ophthalmologists, retinal specialists, and other healthcare providers involved in the care of patients with retinal disorders. This interdisciplinary approach ensures coordinated treatment plans, effective medication management, and timely adjustments based on patient response and clinical outcomes.
Further, hospital pharmacies often have compounding capabilities, allowing them to prepare customized medications and formulations tailored to individual patient needs. This flexibility is particularly beneficial in ophthalmology, specific concentrations or combinations of drugs may be required for optimal treatment outcomes. Thus, driving the growth of the market.

Looking for region specific data?

Download Free Sample

The growth of the retinal disorder treatment market in the U.S., projected to reach USD 11.4 billion by 2032.

The U.S. has rising incidence of diabetes is a significant driver for the market. According to Centers for Disease Control and Prevention (CDC), in 2021, reported that approximately 29.7 million people of all ages in the U.S., representing 8.9% of the population, had diagnosed diabetes. Among children and adolescents under the age of 20 years, there were 352,000 reported cases of diagnosed diabetes, equating to 35 per 10,000 youths in the U.S. This figure includes 304,000 cases of type 1 diabetes.
The U.S. healthcare system benefits from state-of-the-art medical technologies and facilities, including advanced imaging techniques such as OCT (optical coherence tomography) and fundus photography. These technologies are essential for accurate diagnosis and monitoring of retinal disorders.

The retinal disorder treatment market in UK is expected to experience significant and promising growth from 2024 to 2032. The National Health Service (NHS) in the UK provides comprehensive healthcare coverage, ensuring that patients with retinal disorders have access to timely and high-quality care, including regular screenings and specialized treatments.

Japan retinal disorder treatment market is anticipated to witness lucrative growth between 2024 – 2032. Japan has a robust biomedical research ecosystem with leading universities, research institutes, and pharmaceutical companies dedicated to advancing treatments for retinal disorders. Institutions like the University of Tokyo and Kyoto University are renowned for their contributions to ophthalmic research. Japanese researchers and companies are at the forefront of developing innovative therapies, including gene therapies, stem cell-based treatments, and drug delivery systems tailored for retinal diseases.

The retinal disorder treatment market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032. Saudi Arabia has been investing significantly in modern healthcare facilities, including specialized hospitals and medical centers equipped with state-of-the-art diagnostic and treatment technologies.

Retinal Disorder Treatment Market Share

The retinal disorder treatment sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Retinal Disorder Treatment Market Companies

Some of the eminent market participants operating in the retinal disorder treatment industry include:

AbbVie Inc.
Alimera Sciences, Inc.
Alcon, Inc.
Bayer AG
Biogen Inc.
Bausch Health Companies
F. Hoffmann-La Roche Ltd.
Graybug Vision, Inc.
Merck & Co., Inc.
Novartis AG
Ophthotech Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Co. Ltd.
Takeda Pharmaceutical Company Limited

Retinal Disorder Treatment Industry News:

In March 2024, Roche launched Vabysmo (faricimab) for treating neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME). These conditions are leading causes of global vision loss. This launch represents a significant step forward in addressing the treatment needs for nAMD and DME, potentially improving outcomes and quality of life for patients affected by these sight-threatening diseases.
In May 2024, Merck and Eyebiotech Limited (EyeBio) announced acquisition of EyeBio. This acquisition agreement signifies Merck's strategic move to expand its capabilities in the ophthalmology sector, potentially bolstering its portfolio with innovative therapies and technologies developed by EyeBio.

The retinal disorder treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

Diabetic retinopathy
Macular degeneration
- Dry macular degeneration
- Wet macular degeneration
Diabetic macular edema
Retinal vein occlusion
Other types

Market, By Dosage Form

Capsules & tablets
Eye drops
Eye solutions
Gels
Ointments

Market, By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

The above information is provided for the following regions and countries:

North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Retinal disorder treatment industry size was worth USD 13.7 billion in 2023 and will grow at 9.6% CAGR between 2024 and 2032 due to the increasing prevalence of retinal diseases, such as diabetic retinopathy and age-related macular degeneration.

The eye drops segment registered USD 3.8 billion in 2023, driven by their non-invasive nature and ease of administration, making them a preferred choice among patients.

U.S. retinal disorder treatment industry will reach USD 11.4 billion by 2032, attributed to the advanced healthcare infrastructure and high prevalence of retinal diseases like age-related macular degeneration and diabetic retinopathy.

AbbVie Inc., Alimera Sciences, Inc., Alcon, Inc., Bayer AG, Biogen Inc., Bausch Health Companies, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Merck & Co., Inc., Novartis AG, Ophthotech Corporation, and Pfizer, Inc. among others.

Retinal Disorder Treatment Market Scope

Retinal Disorder Treatment Market Size

Retinal Disorder Treatment Market Trends

Retinal Disorder Treatment Market Analysis

Retinal Disorder Treatment Market Share

Buy Now

Premium Report Details

Base Year: 2023
Companies covered: 15
Tables & Figures: 227
Countries covered: 23
Pages: 175

Download Free Sample

`); }});function myfunction33(item) { //alert($(item).data('form-type')); var modal = document.getElementById("myModal"); var form_type = $(item).data('form-type'); // alert(form_type); if (form_type == "requestsample") { $('.form_input_textarea').css("display", "none"); $('.title-request').css("display", "block"); $('.title-ibb').css("display", "none"); $('.title-sectional').css("display", "none"); $('.title-discount').css("display", "none"); $('.title-customize').css("display", "none"); $('.modal-body1').css('margin-top', 0); $('.close').css('margin-top', -108); } else if (form_type == "ibbpopup") { $('.form_input_textarea').css("display", "block"); $('.title-ibb').css("display", "block"); $('.title-request').css("display", "none"); $('.title-sectional').css("display", "none"); $('.title-discount').css("display", "none"); $('.title-customize').css("display", "none"); $('.modal-body1').css('margin-top', 34); $('.close').css('margin-top', -10); } else if (form_type == "requestsample_sectional") { $('.form_input_textarea').css("display", "block"); $('.title-sectional').css("display", "block"); $('.title-request').css("display", "none"); $('.title-ibb').css("display", "none"); $('.title-customize').css("display", "none"); $('.title-discount').css("display", "none"); $('.modal-body1').css('margin-top', 22); $('.close').css('margin-top', -11); } else if (form_type == "custom") { $('.title-customize').css("display", "block"); // $('.form_input_textarea').css("display","none"); // $('.hide-toc').css("display","none"); $('.title-ibb').css("display", "none"); $('.title-sectional').css("display", "none"); $('.title-request').css("display", "none"); $('.title-ibb').css("display", "none"); $('.title-discount').css("display", "none"); // $('.custom_form_name_field').css("display","none"); $('.modal-body1').css('margin-top', 60); $('.close').css('margin-top', -11); } else { $('.title-discount').css("display", "block"); $('.form_input_textarea').css("display", "block"); $('.title-request').css("display", "none"); $('.title-sectional').css("display", "none"); $('.title-ibb').css("display", "none"); $('.modal-body1').css('margin-top', 34); $('.close').css('margin-top', -11); $('.form_input_textarea').css("display", "none"); $('.title-customize').css("display", "none"); } //popup form code start var span = document.getElementsByClassName("close")[0]; // When the user clicks on the button, open the modal $('.sidebar-sticky').removeClass('fixed-sticky'); $('.sticky-head').removeClass('fixed-sticky-head'); $('html').css('overflow', 'hidden'); modal.style.display = "block"; // When the user clicks on the close button (x), close the modal span.onclick = function(event) { event.preventDefault(); // Prevent the default link behavior event.stopPropagation(); // Prevent the event from bubbling up // Hide the modal modal.style.display = "none"; // Reset styles to allow window scrolling $('html').css('overflow', 'auto'); } // When the user clicks anywhere outside of the modal, close it window.onclick = function(event) { if (event.target == modal) { // Hide the modal modal.style.display = "none"; // Reset styles to allow window scrolling $('html').css('overflow', 'auto'); } } //popup code end}